Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)'s Wayne Paterson updates Proactive on the company's first face-to-face annual general meeting (AGM) in three years. Paterson said it was great to meet and reconnect with Anteris shareholders in person, giving them a real sense of what they're invested in. Interestingly, the AGM delivered what could be a world-first: crossing live to the operating room, where investors got to see Anteris' heart valve in action. In fact, the company's second patient cohort, which forms part of its first-in-human study into the DurAVR™ transcatheter heart valve system, has since completed treatment. Paterson is looking forward to announcing some of the study's first results in the future.
Anteris showcases heart valve tech in latest AGM
